S 50131 and S 51434, two novel small molecule glucokinase activators, lack chronic efficacy despite potent acute antihyperglycaemic activity in diabetic mice

Small molecular glucokinase activators: has another new anti-diabetic therapeutic lost favour?

(2012) Matthew G Rees et al.   BRITISH JOURNAL OF PHARMACOLOGY

Small molecule glucokinase activators disturb lipid homeostasis and induce fatty liver in rodents: a warning for therapeutic applications in humans

(2012) Frédéric De Ceuninck et al.   BRITISH JOURNAL OF PHARMACOLOGY

Discovery of Piragliatin—First Glucokinase Activator Studied in Type 2 Diabetic Patients

(2012) Ramakanth Sarabu et al.   JOURNAL OF MEDICINAL CHEMISTRY

Effects of MK-0941, a Novel Glucokinase Activator, on Glycemic Control in Insulin-Treated Patients With Type 2 Diabetes

(2011) G. E. Meininger et al.   DIABETES CARE

Chronic glucokinase activation reduces glycaemia and improves glucose tolerance in high-fat diet fed mice

(2011) Maria Sörhede Winzell et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Variant in the glucokinase regulatory protein (GCKR) gene is associated with fatty liver in obese children and adolescents

(2011) Nicola Santoro et al.   HEPATOLOGY

Hepatic Glucokinase Expression Is Associated with Lipogenesis and Fatty Liver in Humans

(2011) Andreas Peter et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Discovery of (S)-6-(3-Cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic Acid as a Hepatoselective Glucokinase Activator Clinical Candidate for Treating Type 2 Diabetes Mellitus

(2011) Jeffrey A. Pfefferkorn et al.   JOURNAL OF MEDICINAL CHEMISTRY

Management of type 2 diabetes: new and future developments in treatment

(2011) Abd A Tahrani et al.   LANCET

Guidelines for reporting experiments involving animals: the ARRIVE guidelines

(2010) JC McGrath et al.   BRITISH JOURNAL OF PHARMACOLOGY

Animal research: Reporting in vivo experiments: The ARRIVE guidelines

(2010) Carol Kilkenny et al.   BRITISH JOURNAL OF PHARMACOLOGY

Lipids, lipid-lowering therapy and diabetes complications

(2010) P. Valensi et al.   DIABETES & METABOLISM

A small-molecule glucokinase activator lowers blood glucose in the sulfonylurea-desensitized rat

(2010) Sumika Ohyama et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Investigation of Functionally Liver Selective Glucokinase Activators for the Treatment of Type 2 Diabetes

(2009) Gregory R. Bebernitz et al.   JOURNAL OF MEDICINAL CHEMISTRY

Targeting Hepatic Glucokinase in Type 2 Diabetes: Weighing the Benefits and Risks

(2008) L. Agius   DIABETES

Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice

(2008) Catherine Postic et al.   JOURNAL OF CLINICAL INVESTIGATION